Physiomics PLC (GB:PYC)
LSE:PYC
Want to see GB:PYC full AI Analyst Report?
PYC Stock Chart & Stats
0.28 p
0.05 p(6.45%)
At close: 4:00 PM EST
0.28 p
0.05 p(6.45%)
Day’s Range― - ―
52-Week Range0.25 p - 0.80 p
Previous CloseN/A
Volume16.21M
Average Volume (3M)2.43M
Market Cap
£2.38M
Enterprise Value2.10M
Total Cash (Recent Filing)£257.00K
Total Debt (Recent Filing)£0.00
Price to Earnings (P/E)―
Beta0.45
Next Earnings
Sep 24, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding453,208,700
10 Day Avg. Volume1,168,038
30 Day Avg. Volume2,434,740
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)1.60
Price to Sales (P/S)1.41
P/FCF Ratio-2.01
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue Growth MomentumA ~51% revenue rebound in 2025 indicates durable demand for modelling services and improving commercial traction with pharma/biotech clients. Sustained top-line growth supports scale economics for project delivery and strengthens the repeatable project pipeline over the next 2-6 months.
Low Leverage / Clean Balance SheetA debt-free balance sheet reduces refinancing risk and gives management flexibility to invest in business development or absorb temporary cash shortfalls. Low leverage supports strategic options (partnerships, selective hiring) without immediate creditor pressure, improving resilience.
Fee-for-Service Model With Platform UpsideA fee-for-service model ties revenue to client projects, creating repeatable engagement potential with pharma clients. The presence of platform/licence opportunity offers structural upside toward higher-margin recurring revenue and greater client stickiness if adopted, improving long-term margin durability.
Bears Say
Persistent Losses And Weak MarginsContinued net losses and deeply negative margins indicate the business has yet to convert revenue growth into sustainable profitability. Persistent operating losses erode the equity base and limit capacity to reinvest in sales, productisation, or platform development without external funding.
Ongoing Cash BurnRecurring negative operating and free cash flow increases funding risk despite low debt. Ongoing cash burn constrains runway for hiring, product development, or scaling sales; management may need to raise capital or cut growth investments, which can slow progress toward self-sufficiency.
Small Scale And Return Dilution RiskA small equity base and deeply negative ROE mean continued losses quickly dilute shareholder value. The company's limited scale and modest resources reduce margin resilience and bargaining power with larger pharma clients, making growth and profitable scaling more challenging without additional capital.
Physiomics News
PYC FAQ
What was Physiomics PLC’s price range in the past 12 months?
Physiomics PLC lowest share price was 0.25 p and its highest was 0.80 p in the past 12 months.
What is Physiomics PLC’s market cap?
Physiomics PLC’s market cap is £2.38M.
When is Physiomics PLC’s upcoming earnings report date?
Physiomics PLC’s upcoming earnings report date is Sep 24, 2026 which is in 101 days.
How were Physiomics PLC’s earnings last quarter?
Physiomics PLC released its earnings results on Feb 16, 2026. The company reported -0.001 p earnings per share for the quarter, missing the consensus estimate of N/A by -0.001 p.
Is Physiomics PLC overvalued?
According to Wall Street analysts Physiomics PLC’s price is currently Overvalued.
Does Physiomics PLC pay dividends?
Physiomics PLC does not currently pay dividends.
What is Physiomics PLC’s EPS estimate?
Physiomics PLC’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Physiomics PLC have?
Physiomics PLC has 453,208,700 shares outstanding.
What happened to Physiomics PLC’s price movement after its last earnings report?
Physiomics PLC reported an EPS of -0.001 p in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -15.385%.
Which hedge fund is a major shareholder of Physiomics PLC?
Currently, no hedge funds are holding shares in GB:PYC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Physiomics PLC
Founded in 2001 and headquartered in Oxford, UK, Physiomics Plc offers expert consulting services to pharmaceutical enterprises across the United Kingdom, the United States, and the European Union. The company's core specialization lies in outsourced quantitative pharmacology and computational biology. They deliver comprehensive modeling, simulation, and data analysis services primarily focused on oncology research and development, utilizing their proprietary Virtual Tumour predictive software. Additionally, Physiomics is engaged in developing innovative technologies for applications within the field of personalized medicine.